T cells and allogeneic hematopoietic stem cell transplantation. Dr Simonetta's clinical work is mainly focused on Chimeric ...

Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and ...

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today ...

Researchers develop a plug-and-play test that enables real-time monitoring of engineered T-cells, improving the precision and ...

remission among patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), according to data collected from the Real World Outcomes Collaborative for chimeric antigen receptor (CAR ...

To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and ...

The trial used a form of chimeric antigen receptor (CAR) T cell therapy, which has become a mainstay treatment for ...

T cell-based immunotherapies including immune checkpoint blockade and chimeric antigen receptor T cells can induce durable responses in patients with cancer. However, clinical efficacy is limited due ...

A novel test enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient. This simple and innovative test provides ...